{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:39:08Z","timestamp":1794623948983,"version":"4.9.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the efficacy and safety of bimekizumab 160\u2009mg every 4\u2009weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic\/targeted synthetic DMARDs (b\/tsDMARDs) in non-radiographic axial SpA (nr-axSpA) and AS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature review identified randomized controlled trials until January 2023 for inclusion in Bayesian network meta-analyses (NMAs), including three b\/tsDMARDs exposure networks: predominantly-na\u00efve, na\u00efve, and experienced. Outcomes were Assessment of SpondyloArthritis international Society (ASAS)20, ASAS40 and ASAS partial remission (PR) response rates at 12\u201316\u2009weeks. A safety NMA investigated discontinuations due to any reason and serious adverse events at 12\u201316\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The NMA included 36 trials. The predominantly-na\u00efve network provided the most comprehensive results. In the predominantly-na\u00efve nr-axSpA analysis, bimekizumab had significantly higher ASAS20 response rates vs secukinumab 150\u2009mg [with loading dose (LD)\/without LD], and comparable response rates vs other active comparators. In the predominantly-na\u00efve AS analysis, bimekizumab had significantly higher ASAS40 response rates vs secukinumab 150\u2009mg (without LD), significantly higher ASAS-PR response rates vs secukinumab 150\u2009mg (with LD) and comparable response rates vs other active comparators. Bimekizumab demonstrated similar safety to that of other b\/tsDMARDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Across ASAS outcomes, bimekizumab was comparable with most b\/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b\/tsDMARD-na\u00efve nr-axSpA and AS patients at 12\u201316\u2009weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b\/tsDMARDs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead598","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T12:27:58Z","timestamp":1699619278000},"page":"1195-1205","source":"Crossref","is-referenced-by-count":18,"title":["Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis"],"prefix":"10.1093","volume":"63","author":[{"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University , Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology & Department of Neuromuscular Diseases, University College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB Pharma , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma , Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Willems","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Orme","sequence":"additional","affiliation":[{"name":"ICERA Consulting Ltd , Swindon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pritchett","sequence":"additional","affiliation":[{"name":"Source Health Economics , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Rheumatology, University of California, San Francisco , San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2024050221001436300_kead598-B1","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2024050221001436300_kead598-B2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","article-title":"Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy","volume":"6","author":"Robinson","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2024050221001436300_kead598-B4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/rheumatology\/keab544","article-title":"Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study","volume":"61","author":"Boel","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001436300_kead598-B6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","article-title":"Radiographic progression in non-radiographic axial spondyloarthritis","volume":"14","author":"Protopopov","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2024050221001436300_kead598-B7","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/keaa422","article-title":"Non-radiographic versus radiographic axSpA: what\u2019s in a name?","volume":"59","author":"Michelena","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001436300_kead598-B8","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"Lopez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"2024050221001436300_kead598-B9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","article-title":"Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001436300_kead598-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B11","author":"National Axial Spondyloarthritis Society (NASS)"},{"key":"2024050221001436300_kead598-B12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"2024050221001436300_kead598-B13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024050221001436300_kead598-B14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2024050221001436300_kead598-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2008.07.002","article-title":"Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"3","author":"Mitchell","year":"2009","journal-title":"J Crohn\u2019s Colitis"},{"key":"2024050221001436300_kead598-B16","first-page":"S56","article-title":"Extra-articular manifestations","volume":"27","author":"Mielants","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2024050221001436300_kead598-B17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H","article-title":"Health-related quality of life in ankylosing spondylitis: a survey of 175 patients","volume":"12","author":"Ward","year":"1999","journal-title":"Arthritis Care Res"},{"key":"2024050221001436300_kead598-B18","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol"},{"key":"2024050221001436300_kead598-B19","doi-asserted-by":"crossref","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","article-title":"The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data","volume":"10","author":"Cooksey","year":"2015","journal-title":"PLoS One"},{"key":"2024050221001436300_kead598-B20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B21","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2024050221001436300_kead598-B23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2024050221001436300_kead598-B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11926-019-0844-7","article-title":"Current unmet needs in spondyloarthritis","volume":"21","author":"Poddubnyy","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2024050221001436300_kead598-B25","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Comp\u00e1n","year":"2017","journal-title":"RMD Open"},{"key":"2024050221001436300_kead598-B26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23\u2013IL-17 pathway as a therapeutic target in axial spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2024050221001436300_kead598-B27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B28","doi-asserted-by":"crossref","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2024050221001436300_kead598-B29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/BOR.0000000000000805","article-title":"Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis","volume":"33","author":"Yeremenko","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2024050221001436300_kead598-B30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","article-title":"What is the best treatment target in axial spondyloarthritis: tumour necrosis factor \u03b1, interleukin 17, or both?","volume":"57","author":"Poddubnyy","year":"2018","journal-title":"Rheumatology"},{"key":"2024050221001436300_kead598-B32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1759720X17706454","article-title":"Tumor necrosis factor-\u03b1 (TNF\u03b1) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024050221001436300_kead598-B33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B35","author":"Higgins","year":"2022"},{"key":"2024050221001436300_kead598-B36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"2024050221001436300_kead598-B37","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"2024050221001436300_kead598-B38","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"2024050221001436300_kead598-B39","author":"European Medicines Agency","year":"2023"},{"key":"2024050221001436300_kead598-B40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B41","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2024050221001436300_kead598-B42","first-page":"1438","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004"},{"key":"2024050221001436300_kead598-B43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor spondyloarthritis","volume":"17","author":"Landew\u00e9","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2024050221001436300_kead598-B44","first-page":"S33","article-title":"Remission and possible discontinuation of biological therapy in axial spondyloarthritis","volume":"31","author":"Braun","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2024050221001436300_kead598-B45","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","article-title":"Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Cruz-Machado","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001436300_kead598-B46","doi-asserted-by":"crossref","first-page":"151996","DOI":"10.1016\/j.semarthrit.2022.151996","article-title":"Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Ho","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024050221001436300_kead598-B47","doi-asserted-by":"crossref","first-page":"e0244788","DOI":"10.1371\/journal.pone.0244788","article-title":"Impact of tumor necrosis factor alpha inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: a meta-analysis","volume":"15","author":"Huang","year":"2020","journal-title":"PLoS ONE"},{"key":"2024050221001436300_kead598-B48","author":"NICE","year":"2016"},{"key":"2024050221001436300_kead598-B49","author":"Dias","year":"2011."},{"key":"2024050221001436300_kead598-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"PharmacoEconomics"},{"key":"2024050221001436300_kead598-B51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment","volume":"26","author":"Sutton","year":"2008","journal-title":"PharmacoEconomics"},{"key":"2024050221001436300_kead598-B52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/096228020101000404","article-title":"Bayesian methods in meta-analysis and evidence synthesis","volume":"10","author":"Sutton","year":"2001","journal-title":"Stat Methods Med Res"},{"key":"2024050221001436300_kead598-B53","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"Br Med J"},{"key":"2024050221001436300_kead598-B54","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"2024050221001436300_kead598-B55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"2024050221001436300_kead598-B56","author":"Bayesian inference using Gibbs Sampling (BUGS)","year":"2003"},{"key":"2024050221001436300_kead598-B57","author":"Dias","year":"2011"},{"key":"2024050221001436300_kead598-B58","author":"The BUGS project. DIC: Deviance Information Criterion","year":"2023"},{"key":"2024050221001436300_kead598-B59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"2024050221001436300_kead598-B60","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheumatol"},{"key":"2024050221001436300_kead598-B62","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00540-022-03072-5","article-title":"Interpreting and assessing confidence in network meta-analysis results: an introduction for clinicians","volume":"36","author":"Yang","year":"2022","journal-title":"J Anesth"},{"key":"2024050221001436300_kead598-B63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40744-021-00400-1","article-title":"Evidence for the use of secukinumab in patients with radiographic and non-radiographic axial spondyloarthritis in the last 5 years","volume":"9","author":"Aparicio","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024050221001436300_kead598-B64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10787-022-00933-z","article-title":"Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis","volume":"30","author":"Azadeh","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2024050221001436300_kead598-B65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/1744666X.2021.1925541","article-title":"JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials","volume":"17","author":"Keeling","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2024050221001436300_kead598-B66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2024050221001436300_kead598-B67","doi-asserted-by":"crossref","first-page":"705669","DOI":"10.3389\/fphar.2021.705669","article-title":"Risk of malignancy and tuberculosis of biological and targeted drug in patients with spondyloarthritis: systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Man","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024050221001436300_kead598-B68","first-page":"152078","volume-title":"Semin Arthritis Rheum","author":"Pinto","year":"2022"},{"key":"2024050221001436300_kead598-B69","first-page":"1335:63","article-title":"Benefit of biological drugs for quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of clinical trials","author":"Ta\u0144ski","year":"2020","journal-title":"Best Pract Health Care"},{"key":"2024050221001436300_kead598-B70","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10067-020-04970-3","article-title":"A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis","volume":"39","author":"Deodhar","year":"2020","journal-title":"Clinical Rheumatology"},{"key":"2024050221001436300_kead598-B71"},{"key":"2024050221001436300_kead598-B72","year":"2022"},{"key":"2024050221001436300_kead598-B73","first-page":"ii1","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68(Suppl 2)","author":"Sieper","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2024050221001436300_kead598-B74","year":"2021"},{"key":"2024050221001436300_kead598-B75","author":"NICE","year":"2016"},{"key":"2024050221001436300_kead598-B76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10067-017-3693-7","article-title":"Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis","volume":"36","author":"Ungprasert","year":"2017","journal-title":"Clinical Rheumatology"},{"key":"2024050221001436300_kead598-B77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10067-017-3966-1","article-title":"Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"37","author":"Wang","year":"2018","journal-title":"Clinical Rheumatology"},{"key":"2024050221001436300_kead598-B78","author":"Kiri","year":"2020"},{"key":"2024050221001436300_kead598-B79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2022-eular.2534","article-title":"OP0016 efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled phase 3 trial","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B80","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"2024050221001436300_kead598-B81","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/annrheumdis-2022-eular.2518","article-title":"POS0306 efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: a double-blind, randomized, placebo-controlled phase 3 trial","volume":"81","author":"Van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024050221001436300_kead598-B82","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"2024050221001436300_kead598-B83","article-title":"Efficacy and safety of ixekizumab in chinese patients with radiographic axial spondyloarthritis: 16-week results from a phase 3 study [abstract]","volume":"74","author":"Xue","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead598\/53974270\/kead598.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/5\/1195\/57391315\/kead598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/5\/1195\/57391315\/kead598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:02:50Z","timestamp":1714683770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/5\/1195\/7382219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":83,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead598","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,11,8]]}}}